GBP21.28
1.14% day before yesterday
London, Jun 06, 05:35 pm CET
ISIN
GB00B0LCW083
Symbol
HIK
Sector
Industry

Hikma Pharmaceuticals Stock price

GBP21.28
+1.18 5.87% 1M
+2.32 12.21% 6M
+1.71 8.72% YTD
+2.13 11.11% 1Y
+1.05 5.17% 5Y
+5.02 30.87% 10Y
+19.17 908.96% 20Y
London, Closing price Fri, Jun 06 2025
+0.24 1.14%
ISIN
GB00B0LCW083
Symbol
HIK
Sector
Industry

Key metrics

Market capitalization GBP4.64b
Enterprise Value GBP5.45b
P/E (TTM) P/E ratio 17.88
EV/FCF (TTM) EV/FCF 22.39
EV/Sales (TTM) EV/Sales 2.33
P/S ratio (TTM) P/S ratio 1.99
P/B ratio (TTM) P/B ratio 2.77
Dividend yield 2.89%
Last dividend (FY24) GBP0.61
Revenue growth (TTM) Revenue growth 9.77%
Revenue (TTM) Revenue GBP2.33b
EBIT (operating result TTM) EBIT GBP464.96m
Free Cash Flow (TTM) Free Cash Flow GBP243.20m
Cash position GBP157.45m
EPS (TTM) EPS GBP1.19
P/E forward 13.53
P/S forward 1.89
EV/Sales forward 2.22
Short interest 120.00%
Show more

Is Hikma Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Hikma Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Hikma Pharmaceuticals forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Hikma Pharmaceuticals forecast:

Buy
82%
Hold
18%

Financial data from Hikma Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,333 2,333
10% 10%
100%
- Direct Costs 1,263 1,263
16% 16%
54%
1,070 1,070
3% 3%
46%
- Selling and Administrative Expenses 420 420
4% 4%
18%
- Research and Development Expense 104 104
5% 5%
4%
533 533
2% 2%
23%
- Depreciation and Amortization 68 68
5% 5%
3%
EBIT (Operating Income) EBIT 465 465
1% 1%
20%
Net Profit 265 265
89% 89%
11%

In millions GBP.

Don't miss a Thing! We will send you all news about Hikma Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Riad Mishlawi
Employees 9,500
Founded 1978
Website www.hikma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today